OX40 | Tumour necrosis factor (TNF) receptor family | IUPHAR/BPS Guide to PHARMACOLOGY

Top ▲

OX40

target has curated data in GtoImmuPdb

Target id: 1873

Nomenclature: OX40

Systematic Nomenclature: TNFRSF4

Family: Tumour necrosis factor (TNF) receptor family

Annotation status:  image of a grey circle Awaiting annotation/under development. Please contact us if you can help with annotation.  » Email us

Gene and Protein Information
Species TM AA Chromosomal Location Gene Symbol Gene Name Reference
Human 1 277 1p36 TNFRSF4 TNF receptor superfamily member 4
Mouse 1 272 4 E2 Tnfrsf4 tumor necrosis factor receptor superfamily, member 4
Rat 1 271 5q36 Tnfrsf4 TNF receptor superfamily member 4
Previous and Unofficial Names
ACT35 | CD134 | TXGP1L | MRC OX40 | OX40L receptor | Tax-transcriptionally activated glycoprotein 1 | tumor necrosis factor (ligand) superfamily, member 4 | tumor necrosis factor receptor superfamily
Database Links
ChEMBL Target
Ensembl Gene
Entrez Gene
Human Protein Atlas
KEGG Gene
OMIM
RefSeq Nucleotide
RefSeq Protein
UniProtKB
Wikipedia
Natural/Endogenous Ligands
OX-40 ligand {Sp: Human}
Adaptor proteins (Human)
TRAF1, TRAF2, TRAF3, TRAF5

Download all structure-activity data for this target as a CSV file

Antibodies
Key to terms and symbols Click column headers to sort
Antibody Sp. Action Affinity Parameter Reference
MOXR0916 Hs Agonist - - 1
[1]
Antibody Comments
The anti-OX40 monoclonal antibody (mAb) GSK3174998 has entered Phase 1 clinical trial (alone or in combination with the immune checkpoint inhibiting mAb pembrolizumab) as a novel anti-tumour therapy (see NCT02528357). BMS-986178 is another potential immuno-oncolgy anti-OX40 mAb being evaluated in Phase 1/2 clinical trial in patients with advanced solid tumours, in this case either alone or in combination with either of two checkpoint inhibiting mAbs, nivolumab or ipilimumab (see NCT02737475).
Other Binding Ligands
Key to terms and symbols Click column headers to sort
Ligand Sp. Action Affinity Parameter Reference
compound 1 [PMID: 24930776] Hs Binding 5.9 pIC50 2
pIC50 5.9 (IC50 1.2x10-6 M) [2]
Immunopharmacology Comments
The OX40/OX40L pair is involved in late T-cell costimulatory signaling and both are transiently expressed following antigen recognition, and blocking OX40/OX40L is reported to prevent the development of disease in in vivo autoimmune and inflammatory disease models [3].
Immuno Process Associations
Immuno Process:  Inflammation
GO Annotations:  Associated to 1 GO processes
GO:0006954 inflammatory response IBA
Immuno Process:  T cell (activation)
GO Annotations:  Associated to 2 GO processes
GO:0042098 T cell proliferation ISS
GO:0070236 negative regulation of activation-induced cell death of T cells IBA
Immuno Process:  B cell (activation)
GO Annotations:  Associated to 2 GO processes
GO:0030890 positive regulation of B cell proliferation ISS
GO:0051024 positive regulation of immunoglobulin secretion ISS
Immuno Process:  Immune regulation
GO Annotations:  Associated to 3 GO processes
GO:0030890 positive regulation of B cell proliferation ISS
GO:0051024 positive regulation of immunoglobulin secretion ISS
GO:0070236 negative regulation of activation-induced cell death of T cells IBA
Immuno Process:  Cytokine production & signalling
GO Annotations:  Associated to 3 GO processes
GO:0005031 tumor necrosis factor-activated receptor activity IBA
GO:0033209 tumor necrosis factor-mediated signaling pathway TAS
GO:0050710 negative regulation of cytokine secretion IBA
Immuno Process:  Cellular signalling
GO Annotations:  Associated to 2 GO processes
GO:0030890 positive regulation of B cell proliferation ISS
GO:0042098 T cell proliferation ISS
Immuno Process:  Barrier integrity
GO Annotations:  Associated to 1 GO processes, IEA only
click arrow to show/hide IEA associations
GO:0001618 virus receptor activity IEA

References

Show »

1. Huseni M, Totpal K, Du C, Dalpozzo K, Zhu J, Rishipathak D, McNamara E, Jonshtone B, Hegde PS, Rhee I. (2014) Anti-tumor efficacy and biomarker evaluation of agonistic anti-OX40 antibodies in preclinical models. Journal for Immunotherapy of Cancer, 2 (Suppl 3): 105.

2. Song Y, Margolles-Clark E, Bayer A, Buchwald P. (2014) Small-molecule modulators of the OX40-OX40 ligand co-stimulatory protein-protein interaction. Br. J. Pharmacol., 171 (21): 4955-69. [PMID:24930776]

3. Webb GJ, Hirschfield GM, Lane PJ. (2016) OX40, OX40L and Autoimmunity: a Comprehensive Review. Clin Rev Allergy Immunol, 50 (3): 312-32. [PMID:26215166]

Contributors

Show »

How to cite this page

David MacEwan.
Tumour necrosis factor (TNF) receptor family: OX40. Last modified on 22/03/2017. Accessed on 22/05/2019. IUPHAR/BPS Guide to PHARMACOLOGY, http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1873.